Gerd Laux

Gerd Laux

Auto-generated profile, based on publicly available information

Gerd Laux

Institut für Psychologische Medizin (IPM)

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2022 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
GLGerd Laux
Gerd Laux

8 June 2014 in Der Nervenarzt
Verified
Journal Article
Closed access
PDF file
GLG. Laux
G. Laux
ABA. Brunnauer
A. Brunnauer

18 February 2017 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
GLGerd Laux
Gerd Laux
BBBettina Barthel
Bettina Barthel
GHGöran Hajak
Göran Hajak
MLMatthias Lemke
Matthias Lemke
HVHans-Peter Volz
Hans-Peter Volz
Meta-analyses are useful to increase knowledge and strengthen evidence about antidepressant treatment supplementary to individual studies.


28 March 2014 in International Journal of Psychiatry in Clinical Practice
Verified
Journal Article
Closed access
PDF file
GLGerd Laux
Gerd Laux
NHNadja A. Huttner
Nadja A. Huttner
TGthe VIVALDI study group
the VIVALDI study group
Objective. Agomelatine has demonstrated antidepressant efficacy in randomized, controlled trials. This non-interventional study VIVALDI evaluated agomelatine treatment under practice conditions. Methods. Psychiatrists documented the treatment of 3,317 patients over 12 weeks. According to the treatment condition three subgroups were selected: Agomelatine in treatment-naïve patients as mono-therapy (A), in pretreated patients as add-on-therapy (B), and in pretreated patients switched to agomelatine (C). Effect on depressive symptoms was evaluated via svMADRS and CGI. Daytime functioning and sleep–wake rhythm were assessed by a patient-questionnaire. Results. The svMADRS decreased from values > 30 at baseline to 12.8 (total population), 10.3 (A), 15.1 (B), and 13.5 (C). 76.1%, 55.7%, and 62.5% of patients were responders in subgroups A, B, and C, respectively, 65.8% in the total population. Remission was achieved in 66.5% (A), 44.7% (B), and 50.9% (C) of patients. After 12 weeks, subjective sleep quality and daytime functioning improved in the majority of patients. Adverse drug reactions (ADR/serious ADR) were reported for 6.0%/0% (A), 11.0%/0.2% (B), and 12.6%/0.3% (C) of patients. Overall, 25.8% of patients discontinued treatment prematurely, 5.2% due to ADR. Conclusion. Agomelatine improved depressive symptoms, daytime functioning, and sleep–wake rhythm, and demonstrated good tolerability also in pretreated patients and combination therapy under routine practice.

28 January 2015 in Der Nervenarzt
Verified
Journal Article
Closed access
PDF file
GLG. Laux
G. Laux
KSK. Sander
K. Sander
SAS. Artmann
S. Artmann
JDJ. Dreher
J. Dreher
JLJ. Lenz
J. Lenz
IHI. Hauth
I. Hauth